reports
AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Con...
AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference VALENCIA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Cary Vance, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 5:15 p.m. Pacific Time. A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at /events-and-present...
AVITA Medical to Present at the Piper Sandler 37ᵗʰ Annual Healthcare C...
AVITA Medical to Present at the Piper Sandler 37ᵗʰ Annual Healthcare Conference VALENCIA, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 8:30 a.m. EST. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. A live audio webcast of the presentation will be accessi...
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical to Host Investor Webinar Briefing VALENCIA, Calif., Nov. 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on November 12, 2025, at 2:00 p.m. U.S. Pacific Standard Time (November 13, 2025, at 9:00 a.m. Australian Eastern Daylight Time). The webinar presentation will cover fi...
AVITA® Medical Reports Third Quarter 2025 Financial Results
AVITA® Medical Reports Third Quarter 2025 Financial Results VALENCIA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the third quarter ended September 30, 2025. Financial Results Commercial revenue of $17.1 million, representing a 13% decrease compared to the same period in 2024.Cash, cash equivalents, and marketable securities totaled $23.3 million as of Sept. 30, 2025.Operating expenses de...
Data Presented at the 2025 Southern Region Burn Conference Reinforce R...
Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment Global evidence and real-world data demonstrate the clinical, operational, and economic impact of AVITA Medical’s RECELL System across wound types and patient populations VALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced two podium presentations at the 2025 Southern Region Burn Conference (SRBC) that collectively underscore the cli...
AVITA Medical to Announce Third Quarter 2025 Financial Results
AVITA Medical to Announce Third Quarter 2025 Financial Results VALENCIA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2025 financial results after the close of the U.S. financial markets on Thursday, November 6, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 7, 2025, at 8:30 a.m. Australian Eastern Daylight Tim...
AVITA Medical Welcomes Support for RECELL® in Burns in Australia
AVITA Medical Welcomes Support for RECELL® in Burns in Australia Australia’s Medical Services Advisory Committee (MSAC) recognizes RECELL® as safe and effective, with benefits in healing, donor site sparing, and reduced hospital stays VALENCIA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced that Australia’s Medical Services Advisory Committee (“MSAC”) has recommended amendments to the Medicare Benefits Schedule (“MBS”) to include the use of autologous skin cell suspen...
AVITA Medical Announces CEO Transition
AVITA Medical Announces CEO Transition Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independent DirectorThird quarter 2025 preliminary revenue expected to be approximately $17 million VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced that the Board of Directors has named Chairman of the Board Cary Vance as Interim Chief Executive Officer, effective immediately. In conjunction with this appointment, Jim Corbett is lea...
CMS New Technology Add-On Payment Expands Access to RECELL® for Patien...
CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery Effective October 1, the add-on payment eases financial barriers, supporting broader use of RECELL VALENCIA, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company, today announced that beginning October 1, 2025, hospitals across the U.S. will be eligible f...
AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercializat...
AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercialization Across Europe VALENCIA, Calif., Sept. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced it has received the CE Mark under the European Union Medical Device Regulation (EU MDR) for RECELL GO. This allows the Company to commercialize RECELL GO in Europe and in other markets that recognize the CE Mark. “CE Mark for RECELL® GO is an important milestone for AVITA Medical and for patients,” said Jim Corbett, Chief Ex...
Real-World Data Shows Significant Reduction in Hospital Stay Using AVI...
Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System Analysis of U.S. national burn registry data demonstrates 36% shorter hospital stays in adults with deep second-degree burns treated with RECELL versus traditional skin graftingMore than $42,000 per patient cost savings, together with improved patient throughput, support operational and economic value Presented at the 2025 European Burn Association Congress in Berlin, Germany VALENCIA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therap...
AVITA Medical Announces September Investor Conference Participation
AVITA Medical Announces September Investor Conference Participation VALENCIA, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that senior management will participate in three investor conferences this September. Upcoming investor conference participation includes: Cantor Global Healthcare Conference – September 4, 2025 | 10:55 a.m. EST fireside chat with CFO David O’Toole | New YorkMorgan Stanley 23rd Annual Global Healthcare Conference – September ...
AVITA Medical Successfully Completes Australian Equity Raise
AVITA Medical Successfully Completes Australian Equity Raise Private placement of approximately 17.2 million new CHESS Depositary Interests (“New CDIs”) quoted on the Australian Securities Exchange (ASX)Issue price of A$1.32 per New CDI, raising approximately US$15 million (~A$23 million), with participation from new and existing Australian shareholders VALENCIA, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the successful completion of a private p...
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical to Host Investor Webinar Briefing VALENCIA, Calif., Aug. 10, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on August 14, 2025, at 9 AM Australian Eastern Daylight Time (August 13 at 4 PM U.S. Pacific Standard Time). The webinar presentation will cover financial and business res...
AVITA Medical Reports Second Quarter 2025 Financial Results, Updates F...
AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation VALENCIA, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Results Commercial revenue of $18.4 million: Representing an increase of approximately 21% compared to the same period in 2024.Net loss improvement: Net loss for Q2 2025 was $9.9 million, o...
AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to i...
AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance Dr. Tarnoff brings extensive executive and medical leadership experience from various organizations, including Tufts Medical Center and Medtronic.The Board thanks Lou Panaccio, its long-standing Board Chair, for his service as he steps down and Cary Vance assumes the Chair position. VALENCIA, Calif. and MELBOURNE, Australia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company...
AVITA Medical to Announce Second Quarter 2025 Financial Results
AVITA Medical to Announce Second Quarter 2025 Financial Results VALENCIA, Calif. and MELBOURNE, Australia, July 28, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2025 financial results after the close of the U.S. financial markets on Thursday, August 7, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, August 8, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss...
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Red...
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL VALENCIA, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today highlighted data presented by researchers at the British Burn Association (BBA) Annual Meeting demonstrating reduced length of hospital stay among burn patients treated with RECELL®. The session, titled The Clinical Impact of Skin Cell Suspension Autograft from a National Registry Perspective, represents ...
AVITA Medical Announces First Clinical Publication Demonstrating Accel...
AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™ VALENCIA, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the first clinical publication evaluating Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, published in the Journal of Surgery (Akpunonu et al., 2025). According to the investigators, Cohealyx demonstrated significantly faster wound bed vascularization and autograft r...
AVITA Medical’s RECELL Platform Recognized for Surgical Innovation in ...
AVITA Medical’s RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced that RECELLⓇ, including RECELLⓇ GO, has been recognized as the “Best New Technology Solution – Surgical” in the 2025 MedTech Breakthrough Awards. RECELL, FDA-approved for thermal burn wounds and full-thickness skin defects, has treated over 30,000 patients worldwide. RECELL r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.